Anti-cancer drug resistance: Understanding the mechanisms through the use of integrative genomics and functional RNA interference

European Journal of Cancer

Volumn 46, Issue 12, 2010, Pages 2166-2177

  Tan, Daniel S W ^a,b   Gerlinger, Marco ^a,c   Teh, Bin Tean ^b   Swanton, Charles ^a,d  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Biomarker discovery; Chromosomal instability; Drug resistance; Genome instability; Integrative genomics; Next generation sequencing; RNA interference; Targeted therapy; Tumour heterogeneity

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; BIOLOGICAL MARKER; SMALL INTERFERING RNA;

ALTERNATIVE RNA SPLICING; CANCER STEM CELL; CANCER SURVIVAL; CHROMOSOMAL INSTABILITY; CHROMOSOME TRANSLOCATION; COPY NUMBER VARIATION; COST BENEFIT ANALYSIS; DNA METHYLATION; DRUG DEVELOPMENT; DRUG RESISTANCE; FUNCTIONAL GENOMICS; GENE EXPRESSION PROFILING; GENE SILENCING; GENOMIC INSTABILITY; GENOMICS; HEALTH CARE COST; INTEGRATIVE GENOMICS; MONOTHERAPY; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SOLID TUMOR; SOMATIC MUTATION; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC AGENTS; CELL COMMUNICATION; DRUG RESISTANCE, NEOPLASM; GENOMICS; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS; RNA INTERFERENCE; TECHNOLOGY, PHARMACEUTICAL; TUMOR MICROENVIRONMENT;

EID: 77955709954     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.03.019     Document Type: Article

References (152)

1. B. Rubin, and A. Duensing Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors Lab Invest 86 2006 981 986
2. S. Raguz, and E. Yagüe Resistance to chemotherapy: new treatments and novel insights into an old problem Br J Cancer 99 2008 387 391
3. V.T. DeVita, R.C. Young, and G.P. Canellos Combination versus single agent chemotherapy: a review of the basis for selection of drug treatment of cancer Cancer 35 1975 98 110
4. J.H. Goldie, and A.J. Coldman The genetic origin of drug resistance in neoplasms: implications for systemic therapy Cancer Res 44 1984 3643 3653
5. D.L. Dexter, and J.T. Leith Tumor heterogeneity and drug resistance J Clin Oncol: Off J Am Soc Clin Oncol 4 1986 244 257
6. M.A. Shah, and G.K. Schwartz Cell cycle-mediated drug resistance: an emerging concept in cancer therapy Clin Cancer Res: Off J Am Assoc Cancer Res 7 2001 2168 2181
7. J.B. Gibbs Mechanism-based target identification and drug discovery in cancer research Science 287 2000 1969 1973
8. N. Juul, Z. Szallasi, and A.C. Eklund Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials Lancet Oncol 11 2010 358 365
9. P. Selby Acquired resistance to cancer chemotherapy Br Med J (Clinical Research ed) 288 1984 1252 1253
10. H.M. Coley Mechanisms and consequences of chemotherapy resistance in breast cancer Eur J Cancer Suppl 7 2009 3 7
11. P.A. Jänne, N. Gray, and J. Settleman Factors underlying sensitivity of cancers to small-molecule kinase inhibitors Nat Rev Drug Discov 8 2009 709 723
12. L.P. Martin, T.C. Hamilton, and R.J. Schilder Platinum resistance: the role of DNA repair pathways Clin Cancer Res: Off J Am Assoc Cancer Res 14 2008 1291 1295
13. S.J. Welsh, J. Titley, and L. Brunton Comparison of thymidylate synthase (TS) protein up-regulation after exposure to TS inhibitors in normal and tumor cell lines and tissues Clin Cancer Res: Off J Am Assoc Cancer Res 6 2000 2538 2546
14. M. Dean, T. Fojo, and S. Bates Tumour stem cells and drug resistance Nat Rev Cancer 5 2005 275 284
15. K. Goda, Z. Bacso, and G. Szabo Multidrug resistance through the spectacle of P-glycoprotein Curr Cancer Drug Targets 9 2009 281 297
16. C. Swanton, B. Nicke, and M. Marani Initiation of high frequency multi-drug resistance following kinase targeting by siRNAs Cell Cycle (Georgetown, Tex) 6 2007 2001 2004
17. B. Boman, and M. Wicha Cancer stem cells: a step toward the cure J Clin Oncol 26 2008 2795 2799
18. J.M. Rosen, and C.T. Jordan The increasing complexity of the cancer stem cell paradigm Science 324 2009 1670 1673
19. D.J. Slamon, B. Leyland-Jones, and S. Shak Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792
20. M.J. Piccart-Gebhart, M. Procter, and B. Leyland-Jones Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 2005 1659 1672
21. A.C. Wolff, M.E. Hammond, and J.N. Schwartz American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol: Off J Am Soc Clin Oncol 25 2007 118 145
22. P.R. Pohlmann, I.A. Mayer, and R. Mernaugh Resistance to trastuzumab in breast cancer Clin Cancer Res: Off J Am Assoc Cancer Res 15 2009 7479 7491
23. K. Berns, H.M. Horlings, and B.T. Hennessy A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer Cancer Cell 12 2007 395 402
24. J.G. Paez, P.A. Janne, and J.C. Lee EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
25. T.J. Lynch, D.W. Bell, and R. Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
26. W. Pao, V.A. Miller, and K.A. Politi PLoS Med 2 2005 e73
27. P.S. Hammerman, P.A. Janne, and B.E. Johnson Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer Clin Cancer Res 15 2009 7502 7509
28. T.S. Mok, Y. Wu, and S. Thongprasert Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
29. E. Van Cutsem, C.H. Köhne, and E. Hitre Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 2009 1408 1417
30. P.C. Mack, W.S. Holland, and M. Redman J Clin Oncol (Suppl) 27 2009 15s
31. W. Pao, T.Y. Wang, and G.J. Riely KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib PLoS Med 2 2005 e17
32. S.J. Heidorn, C. Milagre, and S. Whittaker Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF Cell 140 2010 209 221
33. R.A. Gatenby, and R.J. Gillies A microenvironmental model of carcinogenesis Nat Rev Cancer 8 2008 56 61
34. M.B. Meads, R.A. Gatenby, and W.S. Dalton Environment-mediated drug resistance: a major contributor to minimal residual disease Nat Rev Cancer 9 2009 665 674
35. Y. Crawford, I. Kasman, and L. Yu PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment Cancer Cell 15 2009 21 34
36. D. Huang, Y. Ding, and M. Zhou Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma Cancer Res 70 2010 1063 1071
37. Y. Shaked, E. Henke, and J.M. Roodhart Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents Cancer Cell 14 2008 263 273
38. G. Bergers, and D. Hanahan Modes of resistance to anti-angiogenic therapy Nat Rev Cancer 8 2008 592 603
39. B. Blouw, H. Song, and T. Tihan The hypoxic response of tumors is dependent on their microenvironment Cancer Cell 4 2003 133 146
40. D. Huang, Y. Ding, and Y. Li Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma Cancer Res 70 2010 1053 1062
41. Y. Xiong, H. Sun, and W. Zhang Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells Clin Cancer Res 15 2009 4838 4846
42. G. Francia, U. Emmenegger, and R.S. Kerbel Tumor-associated fibroblasts as "Trojan Horse" mediators of resistance to anti-VEGF therapy Cancer Cell 15 2009 3 5
43. A. Ostman, and M. Augsten Cancer-associated fibroblasts and tumor growth - bystanders turning into key players Curr Opin Genet Dev 19 2009 67 73
44. K.P. Olive, M.A. Jacobetz, and C.J. Davidson Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer Science 324 2009 1457 1461
45. J. Ludwig, and J. Weinstein Biomarkers in cancer staging, prognosis and treatment selection Nat Rev Cancer 5 2005 845 856
46. J.C. Chang, E.C. Wooten, and A. Tsimelzon Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer Lancet 362 2003 362 369
47. Y. Wang, T. Jatkoe, and Y. Zhang Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer J Clin Oncol: Off J Am Soc Clin Oncol 22 2004 1564 1571
48. Y. Kurokawa, R. Matoba, and H. Nagano Molecular prediction of response to 5-fluorouracil and interferon-alpha combination chemotherapy in advanced hepatocellular carcinoma Clin Cancer Res: Off J Am Assoc Cancer Res 10 2004 6029 6038
49. M. Schmitt, K. Mengele, and E. Schueren European organisation for research and treatment of cancer (EORTC) pathobiology group standard operating procedure for the preparation of human tumour tissue extracts suited for the quantitative analysis of tissue-associated biomarkers Eur J Cancer (Oxford, England: 1990) 43 2007 835 844
50. P. Micke, M. Ohshima, and S. Tahmasebpoor Biobanking of fresh frozen tissue: RNA is stable in nonfixed surgical specimens Lab Invest 86 2006 202 211
51. S.K. Penland, T.O. Keku, and C. Torrice RNA expression analysis of formalin-fixed paraffin-embedded tumors Lab Invest 87 2007 383 391
52. Y. Sugiyama, K. Sugiyama, and Y. Hirai Microdissection is essential for gene expression profiling of clinically resected cancer tissues Am J Clin Pathol 117 2002 109 116
53. R. Dollner, C. Granzow, and B.M. Helmke The impact of stromal cell contamination on chemosensitivity testing of head and neck carcinoma Anticancer Res 24 2004 325 331
54. J.Y. Chung, T. Braunschweig, and R. Williams Factors in tissue handling and processing that impact RNA obtained from formalin-fixed, paraffin-embedded tissue J Histochem Cytochem: Off J Histochem Soc 56 2008 1033 1042
55. C. Greenman, P. Stephens, and R. Smith Patterns of somatic mutation in human cancer genomes Nature 446 2007 153 158
56. M.R. Stratton, P.J. Campbell, and P.A. Futreal The cancer genome Nature 458 2009 719 724
57. T.R. Golub, D.K. Slonim, and P. Tamayo Molecular classification of cancer: class discovery and class prediction by gene expression monitoring Science 286 1999 531 537
58. A. Bhattacharjee, W.G. Richards, and J. Staunton Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses Proc Natl Acad Sci USA 98 2001 13790 13795
59. S.T. Chuang, P. Chu, and J. Sugimura Overexpression of glutathione s-transferase alpha in clear cell renal cell carcinoma Am J Clin Pathol 123 2005 421 429
60. M. Takahashi, X.J. Yang, and S. McWhinney J Med Genet 42 2005 e48
61. X.J. Yang, J. Sugimura, and K.T. Schafernak Classification of renal neoplasms based on molecular signatures J Urol 175 2006 2302 2306
62. C.G. Rogers, J.A. Ditlev, and M.H. Tan Microarray gene expression profiling using core biopsies of renal neoplasia Am J Transl Res 1 2009 55 61
63. M. Takahashi, X.J. Yang, and J. Sugimura Molecular subclassification of kidney tumors and the discovery of new diagnostic markers Oncogene 22 2003 6810 6818
64. B.P. Adley, V. Papavero, and J. Sugimura Diagnostic value of cytokeratin 7 and parvalbumin in differentiating chromophobe renal cell carcinoma from renal oncocytoma Anal Quant Cytol Histol/Int Acad Cytol Am Soc Cytol 28 2006 228 236
65. F. Lin, P.L. Zhang, and X.J. Yang Human kidney injury molecule-1 (hKIM-1): a useful immunohistochemical marker for diagnosing renal cell carcinoma and ovarian clear cell carcinoma Am J Surg Pathol 31 2007 371 381
66. X.J. Yang, J. Sugimura, and M.S. Tretiakova Gene expression profiling of renal medullary carcinoma: potential clinical relevance Cancer 100 2004 976 985
67. K.A. Furge, M.H. Tan, and K. Dykema Identification of deregulated oncogenic pathways in renal cell carcinoma: an integrated oncogenomic approach based on gene expression profiling Oncogene 26 2007 1346 1350
68. K.A. Furge, J. Chen, and J. Koeman Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma Cancer Res 67 2007 3171 3176
69. C.N. Qian, K.A. Furge, and J. Knol Activation of the PI3K/AKT pathway induces urothelial carcinoma of the renal pelvis: identification in human tumors and confirmation in animal models Cancer Res 69 2009 8256 8264
70. S.M. Dhanasekaran, T.R. Barrette, and D. Ghosh Delineation of prognostic biomarkers in prostate cancer Nature 412 2001 822 826
71. K.A. Kelly, S.R. Setlur, and R. Ross Detection of early prostate cancer using a hepsin-targeted imaging agent Cancer Res 68 2008 2286 2291
72. S.M. Mumenthaler, P.Y. Ng, and A. Hodge Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes Mol Cancer Ther 8 2009 2882 2893
73. C.M. Perou, T. Sorlie, and M.B. Eisen Molecular portraits of human breast tumours Nature 406 2000 747 752
74. L.J. van't Veer, H. Dai, and M.J. van de Vijver Gene expression profiling predicts clinical outcome of breast cancer Nature 415 2002 530 536
75. M.J. van de Vijver, Y.D. He, and L.J. van't Veer A gene-expression signature as a predictor of survival in breast cancer N Engl J Med 347 2002 1999 2009
76. M. Buyse, S. Loi, and L. van't Veer Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer J Natl Cancer Inst 98 2006 1183 1192
77. S. Paik, G. Tang, and S. Shak Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer J Clin Oncol 24 2006 3726 3734
78. Y. Hoshida, S. Nijman, and M. Kobayashi Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma Cancer Res 69 2009 7385 7392
79. J. Shendure, and H. Ji Next-generation DNA sequencing Nat Biotechnol 26 2008 1135 1145
80. S.A. Aparicio, and D. Huntsman Does massively parallel DNA resequencing signify the end of histopathology as we know it? J Pathol 220 2010 307 315
81. C. Swanton, and C. Caldas Molecular classification of solid tumours: towards pathway-driven therapeutics Br J Cancer 100 2009 1517 1522
82. P.J. Stephens, D.J. Mcbride, and M. Lin Complex landscapes of somatic rearrangement in human breast cancer genomes Nature 462 2009 1005 1010
83. G.L. Dalgliesh, K. Furge, and C. Greenman Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes Nature 463 2010 360 363
84. E. Pleasance, R.K. Cheetham, and P. Stephens A comprehensive catalogue of somatic mutations from a human cancer genome Nature 463 2010 191 196
85. D.W. Bell Our changing view of the genomic landscape of cancer J Pathol 220 2010 231 243
86. L.D. Wood, D.W. Parsons, and S. Jones The genomic landscapes of human breast and colorectal cancers Science 318 2007 1108 1113
87. S. Jones, X. Zhang, and D.W. Parsons Core signaling pathways in human pancreatic cancers revealed by global genomic analyses Science 321 2008 1801 1806
88. D.W. Parsons, S. Jones, and X. Zhang An integrated genomic analysis of human glioblastoma multiforme Science 321 2008 1807 1812
89. E.J. Fox, J.J. Salk, and L.A. Loeb Cancer genome sequencing - an interim analysis Cancer Res 69 2009 4948 4950
90. L.M. Merlo, J. Pepper, and B. Reid Cancer as an evolutionary and ecological process Nat Rev Cancer 6 2006 924 935
91. R.A. Gatenby A change of strategy in the war on cancer Nature 459 2009 508 509
92. P. Duesberg, R. Stindl, and R. Hehlmann Explaining the high mutation rates of cancer cells to drug and multidrug resistance by chromosome reassortments that are catalyzed by aneuploidy Proc Natl Acad Sci USA 97 2000 14295 14300
93. P. Duesberg, R. Li, and D. Rasnick Aneuploidy approaching a perfect score in predicting and preventing cancer: highlights from a conference held in Oakland, CA in January, 2004 Cell Cycle (Georgetown, Tex) 3 2004 823 828
94. P. Duesberg, and D. Rasnick Aneuploidy, the somatic mutation that makes cancer a species of its own Cell Motil Cytoskeleton 47 2000 81 107
95. P. Duesberg, R. Stindl, and R. Hehlmann Origin of multidrug resistance in cells with and without multidrug resistance genes: chromosome reassortments catalyzed by aneuploidy Proc Natl Acad Sci USA 98 2001 11283 11288
96. C.C. Maley, P.C. Galipeau, and J.C. Finley Genetic clonal diversity predicts progression to esophageal adenocarcinoma Nat Genet 38 2006 468 473
97. S.L. Carter, A.C. Eklund, and I.S. Kohane A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers Nat Genet 38 2006 1043 1048
98. A. Walther, R. Houlston, and I. Tomlinson Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis Gut 57 2008 941 950
99. J. Akervall, X. Guo, and C.N. Qian Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients Clin Cancer Res: Off J Am Assoc Cancer Res 10 2004 8204 8213
100. C. Swanton, B. Nicke, and M. Schuett Chromosomal instability determines taxane response Proc Natl Acad Sci USA 106 2009 8671 8676
101. Navin N, Krasnitz A, Rodgers L, et al. Inferring tumor progression from genomic heterogeneity. Genome Res 2009.
102. R. Clarke, H.W. Ressom, and A. Wang The properties of high-dimensional data spaces: implications for exploring gene and protein expression data Nat Rev Cancer 8 2008 37 49
103. R.F. Service Gene sequencing. The race for the $1000 genome Science 311 2006 1544 1546
104. D. Pushkarev, N.F. Neff, and S.R. Quake Single-molecule sequencing of an individual human genome Nat Biotechnol 27 2009 847 852
105. R. Aebersold, C. Auffray, and E. Baney Report on EU-USA workshop: how systems biology can advance cancer research (27 October 2008) Mol Oncol 3 2009 9 17
106. D. Faratian, R.G. Clyde, and J.W. Crawford Systems pathology - taking molecular pathology into a new dimension Nat Rev Clini Oncol 6 2009 455 464
107. M.E. Gorre, M. Mohammed, and K. Ellwood Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 293 2001 876 880
108. N.P. Shah, C. Tran, and F.Y. Lee Overriding imatinib resistance with a novel ABL kinase inhibitor Science 305 2004 399 401
109. H. Kantarjian, F. Giles, and L. Wunderle Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL N Engl J Med 354 2006 2542 2551
110. S.P. Shah, R.D. Morin, and J. Khattra Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution Nature 461 2009 809 813
111. R.L. Strausberg, and A.J.G. Simpson Whole-genome cancer analysis as an approach to deeper understanding of tumour biology Br J Cancer 102 2010 243 248
112. G. Hu, R.A. Chong, and Q. Yang MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer Cancer Cell 15 2009 9 20
113. Y. Li, L. Zou, and Q. Li Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer Nat Med 16 2010 214 218
114. S. Edwards, R. Brough, and C. Lord Resistance to therapy caused by intragenic deletion in BRCA2 Nature 451 2008 1111 1115
115. R.F.A. McLendon, D. Bigner, and E.G. Van Meir Comprehensive genomic characterization defines human glioblastoma genes and core pathways Nature 455 2008 1061 1068
116. A.J. Lee, R. Kolesnick, and C. Swanton RNAi-mediated functional analysis of pathways influencing cancer cell drug resistance Expert Rev Mol Med 11 2009 e15
117. C. Swanton, M. Marani, and O. Pardo Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs Cancer Cell 11 2007 498 512
118. A.W. Whitehurst, B.O. Bodemann, and J. Cardenas Synthetic lethal screen identification of chemosensitizer loci in cancer cells Nature 446 2007 815 819
119. S.R. Bartz, Z. Zhang, and J. Burchard Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions Mol Cell Biol 26 2006 9377 9386
120. N.C. Turner, C.J. Lord, and E. Iorns A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor EMBO J 27 2008 1368 1377
121. E. Iorns, N.C. Turner, and R. Elliott Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer Cancer Cell 13 2008 91 104
122. J. Downward Cancer: a tumour gene's fatal flaws Nature 462 2009 44 45
123. J. Luo, M.J. Emanuele, and D. Li A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene Cell 137 2009 835 848
124. C. Scholl, S. Frohling, and I.F. Dunn Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells Cell 137 2009 821 834
125. L. Zender, W. Xue, and J. Zuber An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer Cell 135 2008 852 864
126. J.W. Tyner, M.W. Deininger, and M.M. Loriaux RNAi screen for rapid therapeutic target identification in leukemia patients Proc Natl Acad Sci USA 106 2009 8695 8700
127. A.A. Ahmed, A.D. Mills, and A.E. Ibrahim The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel Cancer Cell 12 2007 514 527
128. C. Swanton, Z. Szallasi, and J.D. Brenton Functional genomic analysis of drug sensitivity pathways to guide adjuvant strategies in breast cancer Breast Cancer Res 10 2008 214
129. L.M. McShane, D.G. Altman, and W. Sauerbrei REporting recommendations for tumour MARKer prognostic studies (REMARK) Br J Cancer 93 2005 387 391
130. K. Flaherty, I. Puzanov, and J. Sosman J Clin Oncol 27 2009 15s [Abs 9000]
131. E.L. Kwak, D.R. Camidge, and J.W. Clark J Clin Oncol 27 2009 15s
132. M. Soda, Y.L. Choi, and M. Enomoto Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 448 2007 561 566
133. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009.
134. D.D. Von Hoff, P.M. LoRusso, and C.M. Rudin Inhibition of the hedgehog pathway in advanced basal-cell carcinoma N Engl J Med 361 2009 1164 1172
135. R. Simon The use of genomics in clinical trial design Clin Cancer Res: Off J Am Assoc Cancer Res 14 2008 5984 5993
136. D.S. Tan, G.V. Thomas, and M.D. Garrett Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development Cancer J 15 2009 406 420
137. N. Papadopoulos, K.W. Kinzler, and B. Vogelstein The role of companion diagnostics in the development and use of mutation-targeted cancer therapies Nat Biotechnol 24 2006 985 995
138. Zhu AX, Sahani DV, Duda DG, et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clini Oncol: Off J Am Soc Clin Oncol 2009.
139. P. Workman, E.O. Aboagye, and Y.L. Chung Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies JNCI J Natl Cancer Inst 98 2006 580 598
140. S. Maheswaran, L.V. Sequist, and S. Nagrath Detection of mutations in EGFR in circulating lung-cancer cells N Eng J Med 359 2008 366 377
141. B.J. Druker, M. Talpaz, and D.J. Resta Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 344 2001 1031 1037
142. Y. Nagata, K.H. Lan, and X. Zhou PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients Cancer Cell 6 2004 117 127
143. G. Attard, J.F. Swennenhuis, and D. Olmos Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer Cancer Res 69 2009 2912 2918
144. P. Farmer, H. Bonnefoi, and P. Anderle A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer Nat Med 15 2009 68 74
145. M.E. Straver, A.M. Glas, and J. Hannemann The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer Breast Cancer Res Treat 119 2010 551 558
146. J. Sampath, P.R. Long, and R.L. Shepard Human SPF45, a splicing factor, has limited expression in normal tissues, is overexpressed in many tumors, and can confer a multidrug-resistant phenotype to cells Am J Pathol 163 2003 1781 1790
147. T.S. Lee, W. Ma, and X. Zhang BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations Mol Cancer Therapeutics 7 2008 3834 3841
148. E. San José-Enériz, J. Román-Gómez, and A. Jiménez-Velasco Mol Cancer 8 2009 69
149. H. Yang, W. Kong, and L. He MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN Cancer Res 68 2008 425 433
150. J. Ji, J. Shi, and A. Budhu MicroRNA expression, survival, and response to interferon in liver cancer N Engl J Med 361 2009 1437 1447
151. M.E. Hegi, A.C. Diserens, and T. Gorlia MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 2005 997 1003
152. E.K. Baker, R.W. Johnstone, and J.R. Zalcberg Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs Oncogene 24 2005 8061 8075